Published in Angiogenesis Weekly, June 5th, 2009
"SNS-032 is a potent and selective inhibitor of cyclin-dependent kinases 2, 7 and 9 and inhibits both cell cycle and transcription. We analyzed the effect of SNS-032 (0.5 mc M) on HIF-1 alpha expression and its major trans-regulating factors including...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.